COVID-19 vaccines for all: Decoding global tenders by states
At least a dozen Indian states have floated or will float tenders for procuring vaccines and will also bear the cost
COVID-19: Pfizer, AstraZeneca efficacy significantly reduced against omicron, says UK health agency
Omicron is displaying growth advantage over delta and is poised to become dominant variant in UK
Covaxin effective against UK Strain: What does this mean in absence of efficacy data?
Being a whole-virus vaccine doesn’t give Bharat Biotech product any advantage at this stage, say experts
Gujarat recipients gung-ho on COVID-19 vaccine
The state will vaccinate about 440,000 healthcare workers and 355,000 frontline workers in the first round
COVID-19 vaccine: Oxford-AstraZeneca up to 90% effective in late stage trial
Adenovirus vaccine can be stored at 2-8°C; company to apply for emergency authorisation
COVID-19 Challenge 2021: How does the world overcome vaccine shortage
The pharmaceuticals industry must come together to ensure all adults are vaccinated against the novel coronavirus; …
Coronavirus update: AstraZeneca halts global vaccine trials
COVID-19 has affected 19 sectors in India that were not under stress earlier, with a total Rs 15.5 lakh crore outstanding debt; retail and …
What COVID-19 vaccine side effects might I expect?
In the vast majority of cases, any side effect you feel will be over within a few days, and there is no reason for concern
UK, South African, Brazilian: A virologist explains each COVID-19 variant, what they mean for the pandemic
The take-home message is that variants will emerge, and we need to closely monitor their spread
DCGI clears Bharat Biotech, SII COVID-19 vaccines but efficacy question unanswered
CDSCO official says BB vaccine to be used in public but to exclude people with COVID-19, other infections
Decision on emergency authorisation for SII, Bharat Biotech’s COVID-19 vaccines deferred
Both manufacturers have been asked for more data before a final decision can be reached
Bharat Biotech COVID-19 vaccine claimed to have 80.6% efficacy
'Shot well tolerated in participants; adverse events balanced between vaccine and placebo arms of the trial'